AstraZeneca medicine attains another milestone

BRILINTA® (ticagrelor) tablets achieves further success since receiving FDA approval in July 2011.

AstraZeneca’s BRILINTA® (ticagrelor) tablets have marked another important milestone with their addition to recently released updated key clinical practice guidelines. This recommendation further underscores BRILINTA as a valuable treatment option for health care providers and their patients.

Since receiving FDA approval in July 2011, BRILINTA has now been added to 5 established treatment guidelines. BRILINTA continues to demonstrate its value as an important medicine for appropriate patients.

Please read Medication Guide and full Prescribing Information, including Boxed WARNINGS, for BRILINTA.

To read more about this news, click here.

Stephanie Jacobson, Director, Brand Corporate Affairs at AstraZeneca